All SARS-CoV-2 articles
-
NewsStudy of oral azvudine versus nirmatrelvir/ritonavir in elderly hospitalized COVID-19 patients
A study used five analytical methods to show that oral azvudine has a therapeutic effect in elderly COVID-19 patients aged over 60 years.
-
NewsCertain nasal bacteria may boost the risk for COVID-19 infection, study finds
Certain types of nasal bacteria can affect the levels of key proteins the Covid-19 virus needs to enter human cells, offering new insight into why some people are more vulnerable to the disease than others.
-
NewsInvesting in COVID-19 vaccination more than paid off for U.S., study finds
The US national Covid-19 vaccine strategy more than paid for itself after just one year, according to a new study. Because the vaccines reduced how many people developed serious illness or died, the nation saved more money than it spent.
-
NewsTackling the ‘silent pandemic’: breakthrough study puts first long COVID treatment on horizon
Researchers have shown a new drug compound can prevent long COVID symptoms in mice – a landmark finding that could lead to a future treatment for the debilitating condition.
-
NewsAI learns to ‘speak’ genetic ‘dialect’ for future SARS-CoV-2 mutation prediction
Researchers have developed a new method to predict mutations in virus protein sequences called Deep Novel Mutation Search (DNMS), a type of artificial intelligence model that uses deep neural networks.
-
NewsmRNA-based COVID-19 vaccines train the ‘long-term memory’ of the innate immune system
A study showed that vaccination of multiple mRNA-based COVID-19 vaccines could induce persistent epigenetic changes in innate immune cells, leading to long-term immune responses for SARS-CoV-2 and other pathogens.
-
News‘It’s a shot, not a vaccine like MMR’: New skepticism prompts call for action
This ‘vaccine is not a vaccine’ is a new, previously unreported type of vaccine-specific scepticism, and it arose only during the COVID-19 pandemic. However, it might, according to the researchers, also apply to the flu vaccine.
-
News‘Low-sugar’ vaccine can provide broad immunity against coronavirus variants
A universal vaccine for coronaviruses removes sugar molecules from an area of a coronavirus spike protein that rarely mutates and creates effective and plentiful antibodies to inactivate the virus.
-
NewsUKHSA highlights pathogens of greatest risk to public health in bid to boost preparedness
The UK Health Security Agency (UKHSA) has today published its view on the pathogen families that could pose the greatest risk to public health, in a bid to focus and guide preparedness efforts against these threats.
-
NewsScientists ID natural products targeting SARS-CoV-2 - including caffeine
Researchers used computational methods to identify potential inhibitors of SARS-CoV-2 spike proteins, revealing promising natural compounds for guiding antiviral drug development, including caffeine.
-
NewsAntibody-based therapy is several steps closer to treat lethal mucormycosis
A new paper discusses the use of monoclonal antibodies to target a key fungal cell surface protein, CotH, which enables the Mucorales fungus to invade human cells and cause mucormycosis, which has high mortality rates in people with weakened immune systems.
-
NewsMcMaster leads Canada’s first-ever guidelines for Post COVID-19 Condition
A team of experts from McMaster University has led the creation of Canada’s first-ever comprehensive guidelines for diagnosing, managing, preventing, and treating post COVID-19 condition (PCC), more commonly known as long COVID.
-
NewsCOVID-19 pandemic worsened mother and infant birth outcomes
Mothers who became pregnant after the start of the pandemic, those who experienced moderate-to-severe infections during pregnancy, and those who had infections during the third trimester were more likely to have adverse outcomes.
-
NewsCeSPIACE: A broad-spectrum peptide inhibitor against variable SARS-CoV-2 spikes
CeSPIACE, a small remodified peptide, is able to block the binding of ACE2 receptor and the spike protein on SARS-CoV-2 and its variants. Hence, the cheap and simple peptide could treat COVID-19 infection and prevent reinfection after exposure of the virus.
-
NewsSymptoms of long-COVID can last up to two years after infection with COVID-19
According to a study of the COVICAT cohort, almost one in four people infected with SARS-CoV-2 suffered from long-COVID. In more than half of them the symptoms persisted for two years.
-
NewsCause of post-COVID inflammatory shock in children identified
MIS-C is a serious inflammatory shock that affects children and can occur several weeks after a COVID infection. Researchers have found that reactivation of a pre-existing, dormant infection with the Epstein-Barr virus triggers an excessive inflammatory response.
-
NewsMulti-dose vaccines administered in the same site boost immune response
New research suggests that receiving multiple doses of a vaccine in the same limb leads to faster antibody development, an important strategy for providing immunity as quickly as possible during a pandemic or disease outbreak.
-
NewsInhaled COVID vaccine study begins recruitment for phase-2 human trials
Researchers have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine. Findings from the phase-1 trial indicate that the vaccine is more effective at inducing immune responses than traditional injected vaccines are.
-
NewsBAADesign enables the immune escaped etesevimab fully-armed against SARS-CoV-2 Omicron subvariants
BAADesign offers a powerful tool for reengineering monoclonal antibodies to combat emerging SARS-CoV-2 variants, providing a scalable solution for future pandemic preparedness, according to a new study.
-
NewsScientist who deployed glowing stars to detect disease named fellow of the Royal Society of Chemistry
The man who turned the science of glow-in-the-dark stars into ways to detect disease, Professor Richard Willson, has been elected as a fellow of the Royal Society of Chemistry.